& lt ; Diapulse Corp America > said received permission resume marketing Diapulse pulsed high peak power electromagnetic energy medical device treatment postoperative edema pain superficial soft tissue .
The company said enjoined marketing product U.S. since 1972 due labeling impasse U.S. Food Drug Administration .
It said U.S. District Court Eastern District New York modified injunction sale product following motion filed jointly company FDA .
Reuter & # 3 ; 